Letrozole and LGD-4033 Interaction

Avoid
Mechanism-based 64% confidence

Letrozole and LGD-4033 have a potentially harmful interaction with 64% confidence. Both Letrozole and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

Letrozole

Aromatase Inhibitor | Potent Estrogen Suppression

Letrozole competitively and reversibly binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), inhibiting its catalytic activity with greater potency than any other commercially available aromatase inhibitor. Aromatase catalyzes the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~2 days (48 hours) Typical dose: 0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) pct, anabolic
aromatase androgenicaromatase inhibitorhepatotoxichpta suppressive
View full profile

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Half-life: ~24-36 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskestrogenic
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (Letrozole, LGD-4033). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 hepatotoxic compounds (Letrozole, LGD-4033). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Letrozole, LGD-4033). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Letrozole, LGD-4033). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Letrozole, LGD-4033). Monitor accordingly.

Frequently Asked Questions

Can I take Letrozole with LGD-4033?

Combining Letrozole with LGD-4033 is not recommended. Both Letrozole and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Letrozole and LGD-4033 safe together?

This combination carries significant risk. Both Letrozole and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Letrozole and LGD-4033?

Both Letrozole and LGD-4033 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Letrozole and LGD-4033?

Letrozole has a half-life of ~2 days (48 hours) and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Letrozole vs LGD-4033

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.